BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point InhibitorsElizabeth Dudnik, Jair Bar, Damien Urban et al.|Journal of Thoracic Oncology|2018Cited by 220
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD. Ross Camidge, Shun Lü, Jair Bar et al.|Journal of Clinical Oncology|2024Cited by 131
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataElizabeth Dudnik, Nir Peled, Mor Moskovitz et al.|Lung Cancer|2017Cited by 104
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Alfredo Addeo, Nir Peled et al.|Journal of Thoracic Oncology|2022Cited by 97
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world dataElizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg et al.|OncoImmunology|2021Cited by 70